NY-QUARTILE
Quartile , the leading ad optimization platform for top e-commerce marketplace sellers, today announced it has acquired Sidecar , a performance marketing technology provider for e-commerce retailers and brands that works across all major advertising platforms , including Google, Microsoft Bing, Facebook, Instagram, and Amazon.
The two companies will combine under the Quartile name, growing the brand into the world’s largest cross-channel e-commerce advertising platform. Both platforms apply machine-learning and natural-language processing to provide data-driven strategies and best practices to brand marketers while also offering best-in-class reporting and ad management.
Quartile expects the acquisition to double its amount of advertising spend under management across all platforms to $2 billion in 2021. Unilever, Burt’s Bees and Thrasio are among the more than 5,000 brands currently using the platforms on e-commerce channels like Amazon, Google, Instacart, Walmart, Facebook and Shopify. The combined company will have clients across 26 countries.
"By combining Sidecar's best-in-class solution and expertise managing campaigns for DTC e-commerce merchants with our proprietary AI-driven analytics and optimization platform, we will create the most comprehensive and powerful e-commerce suite," said Daniel Knijnik, co-founder and CEO at Quartile. “The two companies’ complementary businesses, products and relationships will offer unrivaled benefits for our combined customers, employees and other stakeholders across a diverse set of markets.”
"Retail marketers and small businesses are up against great odds when it comes to being seen in online marketplaces. Only 0.1% of products account for around 80% of the sales on e-commerce marketplaces, so brands recognize they need a holistic solution to help them compete in all marketplaces and direct-to-consumer websites,” added Knijnik.
Both Quartile and Sidecar have witnessed exponential growth in recent years as fiercer competition among e-commerce merchants has led to increased advertising spend. Amazon is predicted to grow its ad revenue to $24.47 billion by the end of 2021, an increase of 55.5% year over year, closing the gap as the world's third-largest ad network after Google and Facebook (whose ad revenues grew 34% and 43% , respectively). The platforms provide e-commerce marketers with a critical edge in this fast growing industry.
"We share a passion with the Quartile team for helping small businesses and large retailers grow their exposure, shopping audience, and brands across channels," said Andre Golsorkhi, founder and CEO of Sidecar. "This acquisition is the ultimate example of how we continue to dig in for our customers as their challenges become more complex. By combining the aptitudes and technologies of Sidecar and Quartile, we are continuing to ensure the performance marketing excellence that retailers rely on us for.”
Terms of the acquisition were not disclosed. The combined businesses will comprise a team of more than 300 personnel. Rockbridge Growth Equity, a Detroit-based private equity firm which originally invested a minority stake in Quartile in September of last year, will remain the lead institutional investor in the transaction. Existing Sidecar shareholders will also own a significant stake of the post-acquisition Quartile entity. Investment Bank Canaccord Genuity served as the exclusive financial advisor to Quartile and Rockbridge in connection with the transaction.
“We are thrilled to be partnering with the Sidecar team,” said Kevin Prokop, founder and managing partner at Rockbridge. “The Sidecar team has built an exceptional business. We believe the combination of Quartile and Sidecar creates a distinctive company that is uniquely positioned to capture the exciting opportunities in the e-commerce marketing industry.”
About Quartile:
Founded in 2016, Quartile is an artificial intelligence and machine learning-powered ad optimization platform for leading e-commerce marketplace sellers, such as Amazon, Walmart.com, and Instacart. Quartile’s advertising technology uses proprietary technology and six patented algorithms to make real-time decisions based on accurate data for improved performance and growth. The Quartile platform is an easy-to-use dashboard that equips sellers with the tools to manage their retail media in every marketplace, enabling them to optimize campaigns at the product level to maximize sales, lower the advertising cost of sale (ACoS), and improve margins. For more information visit: www.quartile.com .
About Sidecar:
Sidecar offers performance marketing excellence to retailers and brands. Sidecar’s advanced technology and proprietary data, combined with years of performance marketing expertise, help its customers unlock the full potential of today’s most powerful search, shopping, social, and marketplace channels. For more information, visit: getsidecar.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005819/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom